Cancer Focused Ambrx Biopharma Stock Trading Lower Today - Here's Why
Portfolio Pulse from Vandana Singh
Ambrx Biopharma Inc (NASDAQ:AMAM) announced updated safety and efficacy data from the ongoing Phase 1/2 trial, APEX-01, evaluating ARX517 for metastatic castration-resistant prostate cancer. The data shows promising results, with 7 out of 9 patients experiencing a ≥50% prostate-specific antigen reduction. However, the company's shares are down 30.4% at $9.78.
October 16, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ambrx Biopharma's shares are down 30.4% despite positive results from their ongoing Phase 1/2 trial for ARX517.
Despite the positive results from the ongoing Phase 1/2 trial for ARX517, the company's shares have dropped significantly. This could be due to a variety of factors not mentioned in the article, such as broader market trends or investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100